Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Therapeutic misconception—a false belief that individuals will benefit from participating in research—can bias informed consent. Ethics consultants can help by engaging participants’ and researchers’ understandings of risks and benefits and by asking good questions about the influences of researchers’ enthusiasm.
AMA J Ethics. 2018;20(11):E1100-1106. doi:
10.1001/amajethics.2018.1100.
Case-based teaching, longitudinal application, and training in ethical deliberation can better prepare physicians to responsibly prescribe and manage opioids.
AMA J Ethics. 2019;21(8):E636-641. doi:
10.1001/amajethics.2019.636.
Physicians should provide women considering abortion after Down syndrome screening with unbiased information and not attempt to influence their decision.
AMA J Ethics. 2016;18(4):359-364. doi:
10.1001/journalofethics.2016.18.4.ecas1-1604.